Emerging Economies Biosimilar Sector Potential Reviewed in New Market Study Published at MarketPublishers.com
29 Jun 2012 • by Natalie Aster
LONDON – With patents for major biological drugs facing expiry, pressure on governments in emerging economies to reduce healthcare costs, and the savings that can be obtained with biosimilars over branded biologics, the emerging biosimilars market is likely to keep on expanding in the upcoming years. The market value is expected to increase from USD 3.3 billion in 2010 to USD 8 billion in 2018 at 12% CAGR. The launch of a number of biosimilars that are currently in the late developmental stage in the R&D pipeline, as well as government initiatives to develop the biosimilars market in emerging economies, will also fuel growth.
New market study “Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production” developed by GBI Research provides true insights into the biosimilars market in emerging economies, with regional market forecasts for biosimilars in India and China, and analysis of the key drivers & restraints affecting the sector. The report looks at top companies in the industry through profiles and analysis of their strengths, weaknesses, opportunities and threats; provides analysis of the biosimilars R&D pipeline across various stages of development, details success factors for the industry and the regulatory environment for biosimilars in emerging markets. Further, the study is supplemented with the analysis on major deals that have taken place in the industry from 2007 to 2011.
Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
Published: June, 2012
Price: US$ 3.500,00
More new market studies by the publisher can be found at GBI Research page.